World Health Organization prequalifies New Dengue Vaccine TAK-003 for containing dengue
The World Health Organization (WHO) has granted prequalification to a new dengue vaccine, TAK-003, on 10th of May this year. This marks TAK-003 as the second dengue vaccine to receive such endorsement from the WHO which is next in line to the earlier prequalification of the CYD-TDV vaccine developed by Sanofi Pasteur.
TAK-003 is a live-attenuated vaccine that was developed by the Japanese pharmaceutical company Takeda. It contains weakened versions of the four serotypes of the virus responsible for causing dengue. This innovative vaccine has been specifically recommended by the WHO for children who were of 6 to 16 years and were living in regions with a high burden of dengue and intense transmission rates. The vaccination schedule requires two doses that are administered three months apart.
Dr. Rogerio Gaspar, WHO Director for Regulation and Prequalification, emphasized the importance of this development that the prequalification of TAK-003 is an critical step in the expansion of global access to dengue vaccines, as it is now eligible for procurement by UN agencies including UNICEF and PAHO. With only two dengue vaccines to date prequalified, the research look forward to more vaccine developers coming forward for assessment which can ensure vaccines reach all communities who are in need.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.